Rituximab is associated with worse COVID-19 outcomes in patients with rheumatoid arthritis: A retrospective, nationally sampled cohort study from the U.S. National COVID Cohort Collaborative (N3C)

OBJECTIVE: To assess whether rituximab (RTX) is associated with worse COVID-19 outcomes among patients with rheumatoid arthritis (RA). METHODS: We used the National COVID Cohort Collaborative (N3C), the largest US cohort of COVID-19 cases and controls, to identify patients with RA (International Cla...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Namrata, Madhira, Vithal, Hu, Chen, Olex, Amy L., Bergquist, Timothy, Fitzgerald, Kathryn C., Huling, Jared D., Patel, Rena C., Singh, Jasvinder A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9729169/
https://www.ncbi.nlm.nih.gov/pubmed/36516563
http://dx.doi.org/10.1016/j.semarthrit.2022.152149

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9729169/
https://www.ncbi.nlm.nih.gov/pubmed/36516563
http://dx.doi.org/10.1016/j.semarthrit.2022.152149

Ejemplares similares